Recently, a phase I clinical trial with a small-molecule A2AR antagonist showed that this molecule could safely block adenosine signaling in a cohort of 68 RCC patients who had progressed on PD-1/PD-L1 inhibitors [18]. This evidence concerns the gene PDCD1 and renal cell carcinoma.